Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H20F2N2O3S |
| Molecular Weight | 478.51 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1CCC[C@H]1C(=O)C2=CC=C(C=C2)C3=CC(F)=C(NC4=NC5=CC=C(F)C=C5S4)C=C3
InChI
InChIKey=IOQRTGZPCYYQLE-RTBURBONSA-N
InChI=1S/C26H20F2N2O3S/c27-17-9-11-22-23(13-17)34-26(30-22)29-21-10-8-16(12-20(21)28)14-4-6-15(7-5-14)24(31)18-2-1-3-19(18)25(32)33/h4-13,18-19H,1-3H2,(H,29,30)(H,32,33)/t18-,19-/m1/s1
| Molecular Formula | C26H20F2N2O3S |
| Molecular Weight | 478.51 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:56:40 GMT 2023
by
admin
on
Sat Dec 16 18:56:40 GMT 2023
|
| Record UNII |
CY477RQR44
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CY477RQR44
Created by
admin on Sat Dec 16 18:56:40 GMT 2023 , Edited by admin on Sat Dec 16 18:56:40 GMT 2023
|
PRIMARY | |||
|
44464393
Created by
admin on Sat Dec 16 18:56:40 GMT 2023 , Edited by admin on Sat Dec 16 18:56:40 GMT 2023
|
PRIMARY | |||
|
BAY-74-4113
Created by
admin on Sat Dec 16 18:56:40 GMT 2023 , Edited by admin on Sat Dec 16 18:56:40 GMT 2023
|
PRIMARY | BAY 74-4113: CAS 791593-56-1 | ||
|
300000046507
Created by
admin on Sat Dec 16 18:56:40 GMT 2023 , Edited by admin on Sat Dec 16 18:56:40 GMT 2023
|
PRIMARY | |||
|
791593-56-1
Created by
admin on Sat Dec 16 18:56:40 GMT 2023 , Edited by admin on Sat Dec 16 18:56:40 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antihyperlipidaemic, Obesity therapy; Mechanism of Action: Diacylglycerol O acyltransferase inhibitor; Highest Development Phases: Discontinued for Obesity, Type 2 diabetes mellitus; Most Recent Events: 03 Aug 2009 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route), 07 Nov 2008 Pfizer exits research activities in the area of obesity, 30 Sep 2008 Discontinued - Preclinical for Obesity in USA (unspecified route)
|
||
|
ACTIVE MOIETY |
BAY74-4113-DGAT IC50 = 83 nM;
DGAT IC50 > 10 uM.
|
